Copyright © 2012 American Medical Association. All rights reserved.

Slides:



Advertisements
Similar presentations
Ridker PM, et al. Lancet 2009;373: Baseline clinical characteristics of the study population in the placebo and rosuvastatin groups according.
Advertisements

Date of download: 5/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effects of a Fixed-Dose Combination Strategy on Adherence.
Date of download: 5/30/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Aspirin for the Prevention of Cardiovascular Events.
Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Varespladib and Cardiovascular Events in Patients.
Date of download: 6/10/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effects of Homocysteine-Lowering With Folic Acid.
Date of download: 6/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Major Lipids, Apolipoproteins, and Risk of Vascular.
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Effectiveness of Pharmacist Interventions on.
Date of download: 6/22/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association Between Influenza Vaccination and Cardiovascular.
Date of download: 6/22/2016 Copyright © The American College of Cardiology. All rights reserved. From: Genetic Inhibition of CETP, Ischemic Vascular Disease.
Date of download: 6/26/2016 Copyright © The American College of Cardiology. All rights reserved. From: Plasma triglycerides and type III hyperlipidemia.
Date of download: 6/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Urinary Sodium and Potassium Excretion and Risk of.
Date of download: 6/30/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Cardiorespiratory Fitness as a Quantitative Predictor.
Date of download: 7/1/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Decline in Estimated Glomerular Filtration Rate and.
Date of download: 7/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Oxidation-Specific Biomarkers, Prospective 15-Year.
Date of download: 7/3/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Fibroblast Growth Factor 23 and Risks of Mortality.
Date of download: 7/5/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effects of High vs Low Glycemic Index of Dietary Carbohydrate.
Date of download: 7/8/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Reduced-Function CYP2C19 Genotype and Risk of Adverse.
Baseline characteristics of HPS participants by prior cerebrovascular disease.
Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: Potential Impact of Time Trend of Life-Style Factors.
Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Nonfasting Glucose, Ischemic Heart Disease, and.
Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Implications of Coronary Artery Calcium Testing.
Date of download: 9/19/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Glycated Hemoglobin Measurement and Prediction of.
From: Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality: A Cohort Study Ann Intern Med. 2015;163(5):
From: Genetic Inhibition of CETP, Ischemic Vascular Disease and Mortality, and Possible Adverse Effects J Am Coll Cardiol. 2012;60(20): doi: /j.jacc
Date of download: 11/12/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association of Apolipoprotein E Genotypes With Lipid.
Copyright © 2015 by the American Osteopathic Association.
Copyright © 2011 American Medical Association. All rights reserved.
Copyright © 2014 American Medical Association. All rights reserved.
Copyright © 2015 American Medical Association. All rights reserved.
Copyright © 2003 American Medical Association. All rights reserved.
Copyright © 2011 American Medical Association. All rights reserved.
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies  The Emerging.
Ann Intern Med. 2000;133(6): doi: / Figure Legend:
Copyright © 2011 American Medical Association. All rights reserved.
Copyright © 2011 American Medical Association. All rights reserved.
Copyright © 2000 American Medical Association. All rights reserved.
Copyright © 2002 American Medical Association. All rights reserved.
Copyright © 2009 American Medical Association. All rights reserved.
Copyright © 2007 American Medical Association. All rights reserved.
Low-Density Lipoprotein Cholesterol, Non–High-Density Lipoprotein Cholesterol, Triglycerides, and Apolipoprotein B and Cardiovascular Risk in Patients.
Copyright © 2003 American Medical Association. All rights reserved.
Copyright © 2002 American Medical Association. All rights reserved.
Copyright © 2007 American Medical Association. All rights reserved.
Comparison of baseline characteristics in participants who subsequently had an incident cardiovascular event or new-onset diabetes in the Prospective.
Copyright © 2012 American Medical Association. All rights reserved.
HDL cholesterol and cardiovascular risk Epidemiological evidence
Arterioscler Thromb Vasc Biol
Association of blood lipids with AF
HDL cholesterol and cardiovascular risk
Sunjoo Boo, RN, PhD, Erika Sivarajan Froelicher, RN, PhD, FAAN 
Prehypertension, Diabetes, and Cardiovascular Disease Risk in a Population-Based Sample by Ying Zhang, Elisa T. Lee, Richard B. Devereux, Jeunliang Yeh,
Association of low eosinophil and lymphocyte counts with different initial presentations of cardiovascular disease over the first 6 months ‘Low eosinophils’
Volume 375, Issue 9709, Pages (January 2010)
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report  Terry A. Jacobson, MD, Matthew K. Ito,
Apolipoprotein E-containing high-density lipoprotein (HDL) modifies the impact of cholesterol-overloaded HDL on incident coronary heart disease risk:
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies  The Emerging.
Sunjoo Boo, RN, PhD, Erika Sivarajan Froelicher, RN, PhD, FAAN 
OR (95% CI) for CHD associated with inflammatory markers before and after adjustment for established risk factors. OR (95% CI) for CHD associated with.
Description of studies for pooled analyses
Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies 
Volume 379, Issue 9822, Pages (March 2012)
To B or Not to B: Is Non–High-Density Lipoprotein Cholesterol an Adequate Surrogate for Apolipoprotein B?  Carl J. Lavie, MD, Richard V. Milani, MD, James.
Volume 379, Issue 9822, Pages (March 2012)
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies  The Emerging.
Baseline Characteristics of the Subjects*
Lars E. Laugsand et al. BTS 2016;j.jacbts
Diabetes, prediabetes, and cardiovascular risk: Shifting the paradigm
Volume 75, Issue 1, Pages (January 2009)
ROC curves for cardiovascular events, all-cause mortality, and disease progression. ROC curves for cardiovascular events, all-cause mortality, and disease.
The cumulative incidence curve demonstrated that patients with a sub-optimal LDL-C response to statin therapy were associated with a higher risk of CVD.
Presentation transcript:

Copyright © 2012 American Medical Association. All rights reserved. From: Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With StatinsA Meta-analysis JAMA. 2012;307(12):1302-1309. doi:10.1001/jama.2012.366 Figure Legend: Data markers indicate hazard ratios for risk of major cardiovascular events per 1-SD increase of the lipid or apolipoprotein and 95% CIs. Dashed line indicates point estimate for all participants combined. All interaction terms were by presence or absence of the listed characteristics and were nonsignificant. BMI indicates body mass index; CHD, coronary heart disease; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; and TG, triglyceride. Date of download: 3/9/2018 Copyright © 2012 American Medical Association. All rights reserved.

Copyright © 2012 American Medical Association. All rights reserved. From: Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With StatinsA Meta-analysis JAMA. 2012;307(12):1302-1309. doi:10.1001/jama.2012.366 Figure Legend: Data markers indicate hazard ratios (HRs) for risk of major cardiovascular events per 1-SD increase of on-statin low-density lipoprotein cholesterol (LDL-C), non–high-density lipoprotein cholesterol (non–HDL-C), or apolipoprotein B (apoB) and 95% CIs. For placebo-controlled trials, data from the placebo group were not used in this analysis. Dashed line indicates point estimate for all participants combined. All interaction terms by study were nonsignificant. Date of download: 3/9/2018 Copyright © 2012 American Medical Association. All rights reserved.

Copyright © 2012 American Medical Association. All rights reserved. From: Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With StatinsA Meta-analysis JAMA. 2012;307(12):1302-1309. doi:10.1001/jama.2012.366 Figure Legend: Data markers indicate hazard ratios (HRs) and 95% CIs for risk of major cardiovascular events. Results are shown for 4 categories of statin-treated patients based on whether or not they reached the low-density lipoprotein cholesterol (LDL-C) target of 100 mg/dL and the non–high-density lipoprotein cholesterol (non–HDL-C) target of 130 mg/dL. HRs were adjusted for sex, age, smoking, diabetes, systolic blood pressure, and trial. Date of download: 3/9/2018 Copyright © 2012 American Medical Association. All rights reserved.